Phase 2 trial opens testing PSMA radioligand therapy specifically in Black men with mCRPC
Trial opening · ClinicalTrials.gov · 2026-10-06. Number 5 in the UrologyWatch Top 5 for October 7, 2026.
A phase 2 trial sponsored by Emory University will evaluate the FDA-approved radioligand therapy Pluvicto in African American patients with metastatic castration-resistant prostate cancer, a population underrepresented in prior pivotal trials.
Why it matters: Addresses a known gap in racial representation in PSMA radioligand therapy trial data.
Source: ClinicalTrials.gov
Loading today's edition…